Transplantation Medicine

New drugs, novel use of therapies, enhance transplant success

Published in Blood Weekly, September 26th, 2002

New side-effect sparing drugs and prophylactic uses of acute immunosuppressive therapies such as novel antimetabolites, monoclonal, and polyclonal antibodies are furthering the success of transplants in the organ transplantation field.

New analysis from Frost & Sullivan, "U.S. Organ Transplant Pharmaceuticals Markets," reveals that this industry generated revenues totaling $1.20 billion in 2001. Total market revenues are expected to reach $3.26 billion in 2008.

The need for chronic and acute immunosuppressants is spurred by the need for improved organ transplant outcomes, which are currently plagued by rejection and adverse drug side effects.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry